Length of Therapy with Osimertinib as First-Line Treatment vs Standard EGFR-TKIs Plus Second Line Osimertinib Treatment in Treating Non-Small Cell Lung Cancer Patients with an EGFR Mutation
dc.contributor.advisor | Mathews, Kelly | |
dc.contributor.advisor | Harmon, Mark | |
dc.contributor.author | Patinella, John | |
dc.contributor.author | Patel, Nitesh | |
dc.contributor.author | Puente, Marcos | |
dc.date.accessioned | 2022-06-29T17:12:53Z | |
dc.date.available | 2022-06-29T17:12:53Z | |
dc.date.issued | 2020 | |
dc.identifier.uri | http://hdl.handle.net/10150/665274 | |
dc.description | Class of 2020 Abstract, Report and Poster | |
dc.description.abstract | Specific Aims: Primary aim is to determine if patients initiated with osimertinib had a longer duration of treatment compared to the sum of treatment duration of standard Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs) such as erlotinib, afatinib, and gefitinib plus the use of osimertinib after failure with a standard EGFR-TKI in patients with EGFR-mutated Non-Small Cell Lung Cancer (NSCLC) at a specialty pharmacy. Our secondary aim is to determine if the frequency and severity of adverse events was lower in patients initiated on osimertinib compared to patients who used a standard EGFR-TKI, failed therapy and then used osimertinib. Methods: There were 498 patients who met inclusion criteria and were split into two groups based on their therapy, if they were taking osimertinib as their first-line therapy for NSCLC or taking it after failing a standard EGFR-TKI (EGFR-TKI + osimertinib) from Avella Specialty Pharmacy. Patients in the EGFR-TKI + osimertinib group's duration of therapy was calculated by adding the duration of therapy of their EGFR-TKI to their duration of osimertinib therapy. Adverse events were recorded by type and grading of severity using CTCAE grading scale with 1 being the least severe and 5 being death. Main Results: The 307 patients in the osimertinib as first-line therapy group had a median duration of therapy of 225 days compared to 191 patients in the EGFR-TKI + osimertinib who had a median duration of therapy of 701 days (p-value<0.0001, z-score -14.58). There were 340 adverse events reported (p=0.95) in the osimertinib first-line group with an average grading of 1.6 as compared to 210 adverse events reported in the EGFR-TKI + osimertinib group who had an average grading of 1.6 (p=1). Conclusions: Patients taking osimertinib as a first-line therapy experienced a far shorter duration of therapy than patients who started and failed a standard EGFR-TKI before starting osimertinib in patients with NSCLC in a real-world setting at a specialty pharmacy. There was no difference in adverse events reported between the two groups when considering sample size. | |
dc.language.iso | en | |
dc.publisher | The University of Arizona. | |
dc.rights | Copyright © is held by the author. | |
dc.rights.uri | http://rightsstatements.org/vocab/InC/1.0/ | |
dc.subject | Osimertinib | |
dc.subject | First-line treatment | |
dc.subject | Standard EGFR-TKIs Plus | |
dc.subject | Non-Small Cell Lung Cancer | |
dc.subject | Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs) | |
dc.subject | Avella Specialty Pharmacy | |
dc.subject.mesh | Carcinoma | |
dc.subject.mesh | Non-Small Cell Lung | |
dc.subject.mesh | Inhibitors | |
dc.title | Length of Therapy with Osimertinib as First-Line Treatment vs Standard EGFR-TKIs Plus Second Line Osimertinib Treatment in Treating Non-Small Cell Lung Cancer Patients with an EGFR Mutation | |
dc.type | Electronic Report | |
dc.type | Poster | |
dc.type | text | |
dc.contributor.department | College of Pharmacy, The University of Arizona | |
dc.description.collectioninformation | This item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu. | |
refterms.dateFOA | 2022-06-29T17:12:53Z |